Profile data is unavailable for this security.
About the company
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
- Revenue in USD (TTM)0.00
- Net income in USD-21.97m
- Incorporated1999
- Employees37.00
- LocationenVVeno Medical Corp70 DopplerIRVINE 92618-4306United StatesUSA
- Phone+1 (949) 261-2900
- Fax+1 (949) 261-2992
- Websitehttps://envveno.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VivoSim Labs Inc | 140.00k | -1.98m | 5.22m | 5.00 | -- | 0.7383 | -- | 37.26 | -0.1898 | -0.1898 | 0.068 | 2.71 | 0.017 | -- | 4.59 | 10,769.23 | -24.12 | -51.63 | -34.26 | -56.47 | 98.57 | -- | -1,416.43 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 5.25m | 9.00 | -- | 2.47 | -- | 45.01 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| MetaVia Inc | 0.00 | -16.22m | 5.26m | 9.00 | -- | 0.5703 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.61m | 28.00 | -- | 0.7812 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 5.74m | 1.00 | -- | 2.02 | -- | 955.97 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 5.76m | 0.00 | -- | 2.89 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 5.89m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.11m | 37.00 | -- | 0.1829 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 6.20m | 4.00 | -- | 1.42 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.37m | 1.00 | -- | 0.2482 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.38m | 6.00 | -- | 0.653 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.50m | 22.00 | -- | 0.2783 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.50m | 4.00 | -- | 0.8584 | -- | 1,083.35 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.70m | 37.00 | -- | 0.296 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 6.90m | 2.00 | -- | 0.1297 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to enVVeno Medical Corp's reporting currency: US Dollar USD
24.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2025 | 50.26k | 7.67% |
| Kingdon Capital Management LLCas of 30 Sep 2025 | 38.84k | 5.92% |
| CM Management LLCas of 31 Dec 2025 | 35.71k | 5.45% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.29k | 0.96% |
| Geode Capital Management LLCas of 31 Dec 2025 | 5.75k | 0.88% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 5.67k | 0.87% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2025 | 5.21k | 0.80% |
| Jane Street Capital LLCas of 31 Dec 2025 | 5.11k | 0.78% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 4.41k | 0.67% |
| Simplex Trading LLCas of 31 Dec 2025 | 2.66k | 0.41% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
